|
GA to fingolimod
|
Remaining on GA
|
IM IFN beta-1a to fingolimod
|
Remaining on IM IFN beta-1a
|
SC IFN beta-1a to fingolimod
|
Remaining on SC IFN beta-1a
|
IFN beta-1b to fingolimod
|
Remaining on IFN beta-1b
|
---|
(n = 262)
|
(n = 74)
|
(n = 205)
|
(n = 48)
|
(n = 196)
|
(n = 58)
|
(n = 125)
|
(n = 39)
|
---|
Effectiveness
|
12.16 ± 1.49
|
0.62 ± 2.76
|
13.31 ± 1.48
|
1.37 ± 3.13
|
15.07 ± 1.65
|
1.62 ± 3.02
|
17.59 ± 2.06
|
0.68 ± 3.62
|
Side effects
|
9.25 ± 1.41
|
4.47 ± 2.64
|
30.62 ± 1.56
|
6.56 ± 3.27
|
27.83 ± 1.43
|
-0.42 ± 2.61
|
21.50 ± 1.88
|
-1.24 ± 3.30
|
Convenience
|
38.01 ± 0.80
|
3.11 ± 1.49
|
43.83 ± 0.94
|
5.70 ± 1.97
|
42.36 ± 1.02
|
1.66 ± 1.87
|
41.57 ± 1.15
|
1.31 ± 2.04
|
- Values are displayed as least-squares means ± standard errors. p <0.001 for all comparisons; italics = non-significant result.
- GA, glatiramer acetate; IFN, interferon; IM, intramuscular; SC, subcutaneous; TSQM, Treatment Satisfaction Questionnaire for Medication.